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Expression of decorin, biglycan, and collagen type I in human Extracellular matrix accumulation in mesangial areas
renal fibrosing disease. may contribute to impaired glomerular function in diverse
Background. The extracellular matrix proteoglycans de- human renal diseases, including amyloidosis, diabetic ne-corin and biglycan may have a pathogenic role in renal fibrosing
phropathy, light-chain deposition disease (LCDD), fi-disease via regulation of the activity of growth factors, such as
brillary glomerulonephritis, immunotactoid glomerulo-transforming growth factor-b, and effects on collagen type I
fibrillogenesis. The expression of decorin and biglycan in hu- pathy, and idiopathic mesangial sclerosis. Proteoglycans
man glomerular diseases characterized by mesangial sclerosis are major components of the extracellular matrix that
is unknown. have diverse biologic functions, including binding andMethods. Decorin, biglycan, and collagen type I were local-
inactivation of growth factors, including basic fibroblastized immunohistochemically in human renal biopsy cases of
amyloidosis (N 5 18), diabetic nephropathy (N 5 11), fibrillary growth factor (FGF-2) and transforming growth factor-b
glomerulonephritis (N 5 5), immunotactoid glomerulopathy (TGF-b), and regulation of collagen fibrillogenesis [1, 2].
(N 5 5), light-chain deposition disease (N 5 4), idiopathic Decorin and biglycan are members of the family of small,mesangial sclerosis (N 5 4), and nephrosclerosis (N 5 6),
leucine-rich proteoglycans that may be particularly rele-and in morphologically normal tissues obtained from tumor
vant to the pathogenesis of renal fibrosing injury [3]. Innephrectomies (N 5 8). Decorin and biglycan mRNA synthesis
was evaluated by in situ hybridization. vitro studies have indicated that the synthesis of decorin
Results. Decorin and biglycan protein were not identified in and biglycan by fibroblasts, mesangial cells, and smooth
normal glomeruli. Decorin accumulated in amyloid deposits, muscle cells may be regulated by TGF-b and that decorinbut not in deposits of fibrillary glomerulonephritis or immuno-
may bind and inactivate TGF-b [1, 2]. Further supporttactoid glomerulopathy. Biglycan weakly accumulated in amy-
loid deposits, and both decorin and biglycan weakly stained for a role for decorin as a negative regulator of TGF-b
mesangial nodules in cases of morphologically advanced light- activity comes from in vivo observations in the anti-Thy
chain deposition disease and diabetic nephropathy. In all ana- 1 rat model of mesangioproliferative glomerulonephritis,lyzed cases, irrespective of the underlying disease, decorin and
in which the administration of exogenous decorin [4], orbiglycan accumulated in glomeruli in areas of fibrous organiza-
decorin gene therapy [5], prevented the extracellulartion of the urinary space and in areas of tubulointerstitial fibro-
sis. Biglycan, but not decorin, accumulated in the neointima matrix accumulation that has been attributed to the ac-
of arteriosclerotic blood vessels. Decorin and biglycan mRNA tion of TGF-b. Border and Noble have proposed that a
synthesis was detected at sites of proteoglycan accumulation relative “deficiency” of decorin may contribute to TGF-in glomeruli, interstitium, and neointima. Collagen type I colo-
b–mediated renal injury [6]. The functions of biglycancalized with decorin and biglycan deposits.
Conclusions. Differences in extracellular matrix proteogly- are largely unknown. Besides possible roles in regulating
can composition may be diagnostically useful in distinguishing TGF-b activity and collagen fibril formation, it may alter
morphologically similar diseases. Distinct patterns of proteo- the bioavailability of decorin by competing for a sharedglycan expression may be related to modulation of specific
re-uptake receptor [7]. Determining the expression ofgrowth factor activity in different glomerular diseases.
decorin and biglycan in human renal disease could pro-
vide insights into pathogenesis and could possibly lead
Key words: mesangial sclerosis, proteoglycans, amyloidosis, growth
to the design of novel therapeutic strategies.factor, extracellular matrix, glomerulosclerosis, arteriosclerosis, tubu-
lointerstitial fibrosis. In experimental renal injury, the expression of decorin
and biglycan has been localized to glomerulosclerosisReceived for publication May 10, 1999
lesions and tubulointerstitial fibrosis [7–9]. Decorin, bi-and in revised form August 9, 1999
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ney [7]. In human kidney, decorin has been immunolocal- Antibodies
ized to areas of interstitial fibrosis, but not in glomeruli Polyclonal rabbit antisera LF-51, LF-30/136, and LF-67
[10–12]. Biglycan has been localized in glomeruli and (to human decorin, human biglycan, and human collagen
collecting duct epithelial cells in developing human kid- type I, respectively) were kind gifts of Dr. Larry Fisher
ney [10]. However, the distribution of biglycan in adult (National Institute of Dental Research, Bethesda, MD,
human kidney has not previously been determined. A USA). LF-30/136 was generated against a synthetic pep-
key role for decorin has been postulated in regulating tide corresponding to amino acids 5 to 17 of the core
collagen fibrillogenesis, as demonstrated by the finding protein of human PGII/decorin, conjugated to keyhole
of abnormal collagen fibrils in decorin-deficient mice limpet hemocyanin [19]. LF-51 was generated against a
[13]. Both decorin and biglycan interact with collagen synthetic peptide corresponding to amino acids 11 to
type I in vitro, and codeposition of these molecules has 25 of the core protein of the secreted form of human
been described in various models of fibrosing injury bone PGI/biglycan, conjugated to bovine serum albumin
[14, 15]. (BSA) [19]. LF-67 was generated against 26 amino acids
In this study, we examined the expression of decorin, of a synthetic C telopeptide antigen of the human colla-
biglycan, and collagen type I in human renal tissues dem- gen a I (I) chain [20]. The specificities of these antisera
onstrating a spectrum of glomerulopathies and tubuloin- have been previously confirmed in Western blot and
terstitial fibrosis. Glomerular diseases characterized by immunoprecipitation experiments [15, 19–21].
accumulations of extracellular matrix (mesangial sclero-
sis) were selected to test the hypotheses (a) that decorin Immunohistochemistry
and biglycan are up-regulated in glomerular sclerosing Sections were deparaffinized in xylene and rehydrated
injury, and (b) that differences in extracellular matrix pro- in a descending ethanol series. Endogenous peroxidase
teoglycan composition can be used to distinguish mor- was quenched with 3% H2O2 for 10 minutes. For LF-phologically similar diseases. 30/136 and LF-51 staining, sections were digested with
chondroitinase ABC lyase (ICN Biomedicals, Costa
Mesa, CA, USA) at 250 mU/mL in 0.1 mol/L Tris, 0.01%METHODS
BSA, for 60 minutes at 378C, followed by blocking withTissue selection and pathologic examination
normal goat serum for 10 minutes. For collagen type IArchived paraffin-embedded diagnostic renal biopsy
staining, sections were digested in proteinase K (5 mg/mLtissues from cases of amyloidosis (N 5 18), diabetic ne-
at 378C for 15 min; Sigma, St. Louis, MO, USA). Sectionsphropathy (N 5 11), fibrillary glomerulonephritis (N 5 5),
were incubated with primary antibody and diluted in 1%immunotactoid glomerulopathy (N 5 5), LCDD (N 5 4),
BSA/phosphate-buffered saline (PBS) for one hour atnephrosclerosis (N 5 6), and idiopathic mesangial scle-
room temperature (LF-36/130, 1:250; LF-51 and LF-67,rosis (N 5 4) were selected for study. All cases were
1:500), followed by a biotinylated goat antirabbit anti-characterized by light microscopy, immunofluorescence
body (Vector, Burlingame, CA, USA), ABC-Elite re-microscopy, and electron microscopy, using standard
agent (Vector). The reaction product was visualized withtechniques [16]. Clinical and pathologic data pertaining
3,39 diaminobenzidine (Sigma) and nickel chloride en-to the cases of immuntactoid glomerulopathy have been
hancement. The slides were counterstained with methyldescribed in detail elsewhere [17]. Amyloid deposits
green. Negative controls for immunohistochemistry in-were identified by green/red birefringent Congo Red
cluded substitution of the primary antibody with equalstaining under polarized light. Immunohistochemical
amounts of an irrelevant rabbit IgG (Dako).staining of Congo Red material with a monoclonal anti-
body to amyloid A (AA) protein (Dako, Carpinteria,
Molecular probesCA, USA) were positive in one biopsy. All other cases
Two pBluescript SK plasmids containing either humanof amyloidosis were derived from k or l light chains
bone decorin cDNA (plasmid P2) or human bone bigly-(AL), as demonstrated by routine immunofluorescence
can cDNA (plasmid P16) were generous gifts of Dr.microscopic studies. Idiopathic mesangial sclerosis was
Larry Fisher (National Institute of Dental Research).diagnosed by exclusion of the other causes of mesangial
Plasmid P16 contains a 1658 bp insert with the completesclerosis listed previously in this article [18]. Macroscopi-
protein encoding sequence of the human biglycan genecally normal-appearing renal tissues were obtained from
[21]. Plamid P2 contains a 1.6 kb insert with the proteinnephrectomies (N 5 8) for localized renal carcinoma at
encoding sequence of the human decorin gene [21]. Thesites away from the tumor. Renal biopsy tissues were
plasmids were linearized with Xba I and Kpn I (P16)fixed in 10% neutral-buffered formalin. Portions of ne-
or BamH I and Kpn I (P2) and transcribed into bothphrectomy tissues were fixed in both 10% neutral-buf-
antisense and sense (negative control) riboprobes in T3-fered formalin and in methyl Carnoy’s fixative (60%
methanol, 30% chloroform, and 10% acetic acid). or T7-primed reactions [21], using reagents from Pro-
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Table 1. Localization of decorin, biglycan, and collagen type I in human glomerular disease
Decorin core Decorin Biglycan core Biglycan Collagen
peptide mRNA peptide mRNA type I
Normal 2 2 2 1 MC 2
1 PEC
Amyloidosis 1 1MC 1/2 1 MC 1
1 PEC
LCDD 1/2 2 1/2 1 MC 1/2
1 PEC
Fibrillary glomerulonephritis 2 2 2 1 MC 2
1 PEC
Immunotactoid glomerulopathy 2 2 2 1 MC 2
1 PEC
Idiopathic mesangial sclerosis 2 2 2 1 MC 2
1 PEC
Diabetic nephropathy 1/2 2 1/2 1 MC 1/2
1 PEC
Nephrosclerosis 1u 1MC 1u 1 MC 1u
1 PEC
Abbreviations are: MC, mesangial cells; PEC, parietal epithelial cells; LCDD, light-chain deposition disease; u, fibrous organization of urinary space; 1, positive;
2, negative; 6, weakly and/or focally positive
mega (Madison, WI, USA; except 35S-UTP, obtained in tumor nephrectomies), variably increased mesangial
from New England Nuclear, Boston, MA, USA). matrix and mesangial hypercellularity, capillary wall
thickening, and nodular mesangial sclerosis. Many tis-
In situ hybridization sues also showed focal and segmental glomerulosclerosis
Formalin-fixed, paraffin-embedded tissues were de- and obsolescent (globally sclerotic) glomeruli. Some glo-
paraffinized following standard protocol. The sections meruli showed ischemic changes consisting of wrinkling
were washed with 0.5 3 standard sodium citrate (SSC; of glomerular basement membranes and fibrous thick-
GIBCO, Grand Island, NY, USA) and digested with 5 ening of Bowman’s capsules. There was variable intersti-
mg/mL proteinase K (Sigma) in Tris buffer (500 mmol/L tial fibrosis, usually accompanied by a patchy, nonspecific
NaCl, 10 mmol/L Tris, pH 8.0) for 30 minutes at 378C. mononuclear inflammatory cell infiltrate. Arterial ves-
Several 0.5 3 SSC washes were followed by prehybrid- sels frequently showed arteriosclerosis. Arteriolar hyali-
ization for two hours in 50 mL of prehybridization buffer nosis and arterial amyloid deposits were identified in
[50% formamide, 0.3 mol/L NaCl, 20 mmol/L Tris, pH
individual cases. The severity of glomerulosclerosis, tu-8.0, 5 mmol/L ethylenediaminetetraacetic acid (EDTA),
bulointerstitial fibrosis, and arteriosclerosis was rela-1 3 Denhardt’s solution, 10% dextran sulfate, 10 mmol/L
tively consistent within individual cases.dithiothreitol (DTT), 500 mg/mL yeast tRNA] at 508C.
The hybridization was started by adding 500,000 cpm of Immunolocalization and mRNA expression of decorin35S-labeled riboprobe in 50 mL of prehybridization buffer
The results of immunohistochemical and in situ hy-and was allowed to proceed overnight at 508C. Sections
bridization studies for decorin are summarized in Tablewere then washed with 0.5 3 SSC, followed by RNase
1 and Figure 1. Decorin protein and mRNA were notA (20 mg/mL, 30 min at room temperature), 2 3 SSC
identified in morphologically normal glomeruli (Fig. 1washes (2 3 2 min), three high-stringency washes with
A, E, and F). A distinct pattern of decorin expression0.1 3 SSC/0.1% Tween 20 (Sigma) at 508C, and several
was evident in different glomerular diseases. Decorin2 3 SSC washes. The slides were dipped in NTB2 nuclear
emulsion (Kodak, Rochester, NY, USA) and exposed in localized to amyloid deposits, in glomeruli, tubulointer-
the dark at 48C for one to four weeks. After developing, stitium, and arterial walls (Figs. 1 B, H, and J). The
sections were counterstained with hematoxylin and eosin intensity and distribution of decorin immunostaining
and were dehydrated and coverslipped. Positive cellular correlated with staining for Congo Red in individual
labeling was defined as five or more silver grains in a cases. Deposits of both AA and AL amyloid showed a
single cell. For negative controls, simultaneous hybrid- similar reaction. No significant immunostaining for de-
ization with the sense riboprobe was performed on repli- corin was identified in mesangial areas in most cases of
cate tissue sections. diabetic nephropathy, LCDD, fibrillary glomerulone-
phritis, immunotactoid glomerulopathy, or idiopathic
RESULTS mesangial sclerosis (Fig. 1C). Occasional glomeruli with
Histologic examination features of nodular mesangial sclerosis in some cases
of LCDD or diabetic nephropathy demonstrated weak,Tissues demonstrated a spectrum of histologic pat-
terns, including normal glomerular morphology (mostly focal staining for decorin (data not shown). Decorin pro-
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Fig. 1. Localization of decorin protein and mRNA in human kidney.
(A) No immunohistochemical staining for decorin in a histologically
normal glomerulus (from a tumor nephrectomy specimen). (B) De-
corin accumulates in amyloid deposits in mesangium. (C ) Decorin is
absent in mesangial nodules in a case of light chain deposition disease
(LCDD). (D) Accumulations of decorin in fibrotic areas formerly
comprising the urinary space (arrows) in a case of nephrosclerosis.
(E and F ) Decorin mRNA is not identified in histologically normal
glomerulus (low and high power). (G) Cells expressing decorin mRNA
(black silver grains) in amyloidotic glomerulus are indicated by arrow-
heads. (H ) Decorin localizes to peritubular amyloid deposits (arrows).
(I ) Decorin accumulation in an area of interstitial fibrosis (arrow). (J )
Decorin localizes to arterial wall amyloid deposits (arrow; same case
as Fig. 1B). (K ) Decorin accumulates in adventitia (arrow) but not in
media or neointima (*) of artery. (L) Decorin mRNA expression in
interstitial cells (arrows). (M) No hybridization signal with decorin
control sense riboprobe [methyl green counterstain (A–D, H–K), he-
matoxylin and eosin counterstain (E–G, L), and (M)]. Original magni-
fication A–D, H–K 3400; E–G, L, and M 31000.
tein accumulated in scarred glomeruli in which the uri- In the tubulointerstitial compartment, decorin accu-
mulated in expanded zones of interstitial fibrosis (Fig.nary space was obliterated, with fibrous adhesion of the
glomerular tuft to Bowman’s capsule (Fig. 1D). This 1I). The intensity of decorin immunostaining showed
some variation between cases, but appeared to correlatefinding was especially prominent in cases of nephroscl-
erosis, but was also present to a variable degree in many with the degree of tubulointerstitial fibrosis, irrespective
of disease category. Decorin mRNA expression was de-of the other diseased tissues examined. By in situ hybrid-
ization, decorin mRNA expression was detectable within tectable in occasional peritubular interstitial cells resem-
bling interstitial fibroblasts or myofibroblasts (Fig. 1L)some sclerosed glomeruli, including amyloidotic glomer-
uli (Fig. 1G). [22]. Decorin mRNA-expressing cells appeared more
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numerous in expanded areas of interstitial fibrosis that from the intima of morphologically normal arteries and
was rarely identified in the neointima of arterioscleroticfrequently showed mononuclear inflammatory cell ag-
gregates, but the hybridization signal was not clearly vessels. Cells expressing decorin mRNA were identified
in the adventitia but not in the media or intima of bloodidentified in mononuclear inflammatory cells or in tubu-
lar epithelial cells. vessel walls (data not shown). Other than the association
of decorin with amyloid deposits noted earlier in thisIn arterial vessels, decorin was localized predomi-
nantly in the adventitia (Fig. 1K), with only focal staining article, no specific pattern of decorin immunostaining
was identified in tubulointerstitium or arterial vessels inin the media, between smooth muscle cells, particularly
in larger (arcuate-sized) arteries. Decorin was absent the other disease categories examined.
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Fig. 2. Localization of biglycan protein and mRNA in human kidney.
(A) No immunohistochemical staining for biglycan in histologically
normal glomerulus (from a tumor nephrectomy specimen). Note the
positive staining in surrounding interstitial fibrosis. (B) Weak biglycan
staining (arrow) in amyloidotic glomerulus (same case as Fig. 1B). (C )
Biglycan accumulates at periphery of mesangial nodules (arrowheads)
in a case of LCDD (same case as Fig. 1C). Also, note staining of
fibrotic region of the urinary space adjacent to Bowman’s capsule (*; D).
Biglycan accumulates in fibrotic region adjacent to Bowman’s capsule
(*). (E) Biglycan mRNA expression in parietal epithelial cells (arrows)
and cells in a location consistent with mesangial cells (arrowheads) in
histologically normal glomerulus. (F ) Biglycan does not localize to
peritubular amyloid deposits (same case as Fig. 1H). (G) Accumula-
tions of biglycan in areas of interstitial fibrosis. (H ) Biglycan accumu-
lates in neointima (*) of arteriosclerotic vessel. (I ) Biglycan mRNA
expression in numerous neointimal cells and media smooth muscle
cells (arrowheads). Double arrows indicate position of internal elastic
lamina. (J ) Biglycan mRNA expression in interstitial fibroblasts. (K )
No hybridization signal with sense riboprobe. Methyl green counter-
stain (A–D, F–H), hematoxylin and eosin counterstain (E, I–K). Origi-
nal magnification A–D, F–H, 3400; E, I–K, 31000.
Immunolocalization and mRNA expression of amyloidosis (Fig. 2B), diabetic nephropathy, and
of biglycan LCDD. In some of these glomeruli, biglycan staining
was localized to the periphery of mesangial nodules (Fig.Biglycan peptide was not detected in morphologically
2C). Biglycan did not accumulate in mesangial areasnormal glomeruli (Table 1 and Fig. 2A). No distinct
in cases of fibrillary glomerulonephritis, immunotactoidpattern of biglycan expression was identified in the dif-
glomerulopathy, or idiopathic mesangial sclerosis. Accu-ferent glomerular diseases examined. Mesangial areas
focally showed weak staining for biglycan in some cases mulations of biglycan were identified in scarred glomer-
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uli in which the urinary space was obliterated, with fi- In morphologically normal kidneys, collagen type I
localized to the interstitium, particularly in the medullabrous adhesion of the glomerular tuft to Bowman’s
capsule, in a similar distribution to that observed for (data not shown). Collagen type I accumulated in ex-
panded zones of interstitial fibrosis (Fig. 3F). Collagendecorin (compare Fig. 1D and Fig. 2D). By in situ hybrid-
ization, biglycan mRNA localized to parietal epithelial type I localized to the adventitia and, focally, to the
cells and, focally, to intraglomerular cells (Fig. 2E) in media of morphologically normal arteries, but was not
both morphologically normal and sclerosed glomeruli. detected in normal intima. In the neointima of arterio-
Biglycan did not localize to peritubular or interstitial sclerotic vessels, diffuse accumulations of collagen type
amyloid deposits (Fig. 2F). The distribution of biglycan I were observed in a parallel distribution to that observed
in the tubulointerstitium overlapped with that of decorin for biglycan (compare Fig. 2H and Fig. 3H).
(compare Fig. 1H and Fig. 2G), with accentuation in
vascular adventitia and diffuse staining in expanded ar-
DISCUSSIONeas of interstitial fibrosis. Biglycan mRNA expression
The present study is the first to our knowledge towas seen in peritubular interstitial fibroblasts or myofi-
describe the synthesis and deposition of the proteogly-broblast-like cells, which were more numerous in areas
cans decorin and biglycan in human glomerular diseasesof interstitial fibrosis (Fig. 2J). No hybridization signal
characterized by accumulations of extracellular matrix.for biglycan was identified in tubular epithelial cells or
The demonstration of decorin and biglycan expression atin infiltrating mononuclear inflammatory cells.
sites of glomerular fibrosing injury and tubulointerstitialBiglycan peptide localized to the adventitia and, fo-
fibrosis supports a pathogenic role for these proteogly-cally, to the media of morphologically normal arteries,
cans in progressive human renal disease. Differences inbut was not detected in normal intima (data not shown).
proteoglycan composition may be diagnostically usefulAccumulations of biglycan were diffusely present in the
in distinguishing morphologically similar glomerular dis-neointima of arteriosclerotic vessels (Fig. 2H). Biglycan
eases. The finding that decorin colocalizes with amyloidmRNA was identified in occasional smooth muscle cells
deposits, but not in diabetic nephropathy, LCDD, fibril-in the media and in neointimal cells (Fig. 2I), but not in
lary glomerulonephritis, and immunotactoid glomerulo-endothelial cells.
pathy, supports the existence of different pathways of
Immunolocalization of collagen type I mesangial sclerosis in these diseases, which may be re-
lated to the modulation of specific growth factors byCollagen type I protein was not identified in morpho-
proteoglycans.logically normal glomeruli (Table 1 and Fig. 3A). In
The colocalization of decorin with amyloid depositsglomerular disease, collagen type I colocalized with de-
in glomeruli, tubulointerstitium, and arterial blood vesselcorin and biglycan. Intense immunostaining for collagen
walls is striking and strongly suggests a pathogenic roletype I was observed in amyloid deposits, in glomeruli,
for this proteoglycan in the formation of amyloid depos-tubular basement membranes, and artery walls, in a pat-
its. Although there is considerable experimental evi-tern identical to that of decorin (Fig. 3 B, E, and G).
Collagen type I expression was similar in cases of AA dence to support a role in amyloidogenesis for basement
membrane-derived extracellular matrix components, in-and AL. Weak immunostaining for collagen type I was
identified in mesangial nodules in some cases of LCDD cluding heparan sulfate proteoglycan, laminin, and colla-
gen type IV [23–25], few studies have examined the dis-and diabetic nephropathy that also showed staining for
decorin and/or biglycan (Fig. 3C). No immunostaining tribution of nonbasement membrane proteoglycans in
amyloidotic tissues. Decorin has previously been local-for collagen type I was identified in mesangial areas
in cases of fibrillary glomerulonephritis, immunotactoid ized to the periphery of Ab amyloid deposits in the brain
[26], and both decorin and biglycan have been localizedglomerulopathy, or idiopathic mesangial sclerosis. Colla-
gen type I also colocalized with decorin and biglycan in by immunoelectron microscopy in glomerular deposits
of AA [27]. The identification of decorin mRNA synthe-glomeruli with features of fibrous organization of Bow-
man’s space (compare Fig. 1D, Fig. 2D, and Fig. 3D). sis in amyloidotic glomeruli, but not in morphologically
b
Fig. 3. Localization of collagen type I at sites of fibrotic injury. (A) There is no immunohistochemical staining for collagen type I in a histologically
normal glomerulus. (B) Collagen type I accumulates in amyloid deposits in mesangium (same case as Fig. 1B). (C ) Collagen type I localizes to
the periphery of mesangial nodules (arrowheads) in a case of LCDD (compare with Fig. 2C). (D) Accumulations of collagen type I in fibrotic
glomerulus (arrows; compare with Fig. 1B and Fig. 2B). (E) Collagen type I localizes to peritubular amyloid deposits (compare with Fig. 1H). (F )
Collagen type I staining in areas of interstitial fibrosis. (G) Collagen type I localizes to amyloid deposits (arrows) in arterial wall (compare with
Fig. 1J). (H ) Collagen type I accumulates in neointima (arrow; compare with Fig. 2H). Methyl green counterstain (A–H). Original magnification
A–H 3400.
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normal glomeruli, suggests that local up-regulation of to unregulated TGF-b activity at these sites. Alterna-
decorin synthesis contributes to the accumulation of pro- tively, binding of growth factors to extracellular matrix
teoglycan in these cases. The colocalization of collagen proteoglycans may serve a reservoir function, increasing
type I with amyloid has not been reported in the litera- the availability of growth factors at sites of fibrosing
ture. Our study raises the possibility that codeposition injury.
of decorin and collagen type I may have a role in stabili- Peritubular interstitial fibroblasts expressing decorin
zation and persistence of amyloid deposits. mRNA and biglycan mRNA were more numerous in
The finding of weak staining for decorin and biglycan areas of interstitial fibrosis compared with morphologi-
in some cases of advanced LCDD and diabetic nephrop- cally normal tubulointerstitium, suggesting that proteo-
athy was also related to the focal finding of collagen type I glycan synthesis may be up-regulated in areas of intersti-
deposits in these tissues. Although there is experimental tial fibrosis. Biglycan mRNA, as distinct from biglycan
evidence that mesangial cell synthesis of decorin is up- peptide expression, was identified in parietal epithelial
regulated in hyperglycemic cell culture media [28] and cells and in occasional intraglomerular cells in both mor-
in rodent models of diabetic glomerular disease [29], the phologically normal and sclerotic glomeruli. The role of
results of our study do not support a role for up-regulated increased biglycan synthesis in the formation of biglycan
synthesis and deposition of decorin and biglycan in the accumulations in glomeruli remains undetermined. Of
pathogenesis of human diabetic nephropathy, and in note, other investigators have described a somewhat dif-
most clinically important human glomerular diseases ferent distribution of biglycan in the kidney. In rat kidney,
characterized by mesangial sclerosis. An important ca- biglycan mRNA and core protein have been localized to
veat is that the tissues examined in this study were ob- glomerular capillaries, mesangial cells, and podocytes
tained from individuals with symptomatic renal disease, and in collecting ducts and distal tubules [7, 35]. In hu-
and these investigations do not address the possibility man fetal kidney, Bianco et al have localized biglycan
that decorin and biglycan may have functions in earlier protein on the surface of endothelial cells and collecting
stages of glomerular injury. Further studies to examine tubules and “very occasionally” in parietal epithelial cells,
the expression of these extracellular matrix molecules and they have also localized mRNA to these cells [10].
in more acute forms of glomerular injury, characterized The results of this study, in which biglycan mRNA syn-
by cellular proliferation and mesangiolysis, will help to thesis was not identified in endothelium or collecting
define better the roles of decorin and biglycan in human ducts, suggest that biglycan expression by endothelial
glomerular disease. cells and tubular epithelial cells may be developmentally
The codistribution of decorin and biglycan with colla- restricted, perhaps reflecting different biologic functions
gen type I in glomerulosclerosis and interstitial fibrosis
in developing and mature human kidney.
suggests that synthesis and/or deposition of these extra-
Biglycan, but not decorin, was identified in the neoin-cellular matrix moieties may be pathogenically related.
tima of arteriosclerotic blood vessels. Distinct patternsDecorin has a key role in regulating collagen fibril assem-
of localization of decorin and biglycan have also beenbly and growth, as demonstrated by the finding of abnor-
described in human coronary atherosclerotic plaques [15,mal collagen fibrils in decorin-deficient mice [13], and
36], in restenosis lesions following coronary angioplastyinteractions between biglycan and collagen type I have
[15], and in coronary transplant arteriopathy [31]. Basedalso been described in vitro [14]. The codeposition of
on the demonstration of specific interactions betweendecorin and biglycan with collagen type I has been de-
biglycan and apolipoprotein E in vitro, and the immuno-scribed in other instances of fibrosing injury, including
histochemical colocalization of biglycan with apolipo-arteriosclerotic blood vessels [15, 30, 31], myocardial in-
protein E in human coronary atherosclerotic plaques, itfarction [32], and keloids [33]. Proteoglycan-collagen
has been proposed that interactions between proteogly-type I interactions may contribute to stabilization of the
cans and lipoproteins may contribute to the pathogenesisremodeled extracellular matrix at sites of fibrosing in-
of atherosclerosis by trapping lipoproteins in the arteryjury. Decorin and biglycan bound to collagen fibrils may
wall [36]. The finding of distinct and overlapping patternsbe sequestered from the normal pathway of reuptake
of decorin and biglycan accumulation in the kidney sug-and receptor-mediated endocytosis [2], thus contributing
gests specific, albeit as yet undetermined pathogenicto the formation of immunohistochemically detectable
roles in human renal fibrosis that may be related todeposits at sites of collagen type I deposition. This inter-
different biologic properties of these molecules. How-pretation is consistent with in vitro observations of de-
ever, the pathogenesis of proteoglycan accumulation inlayed turnover of proteoglycans synthesized by fibro-
fibrotic disease is complex and multifactorial, and otherblasts grown on a collagenous matrix [34]. It is interesting
factors not examined in this study, such as local differ-to speculate that binding of proteoglycans to collagen
ences in activity of profibrogenic cytokines [37] and ma-may lead to reduced availability of these molecules for
interactions with growth factors, such as TGF-b, leading trix degrading enzymes, are likely to be important in
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12. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miya-determining the topographic distribution of proteogly-
moto H, Maki S: Transforming growth factor-beta protein and
cans in human renal fibrosing injury. mRNA in glomeruli in normal and diseased human kidneys. Lab
Invest 68:154–163, 1993In summary, decorin and biglycan contribute to the
13. Danielson KG, Baribault H, Holmes DF, Graham H, Kadlerpathologic accumulations of extracellular matrix that
KE, Iozzo RV: Targeted disruption of decorin leads to abnormal
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